Priced at just $169,000 Vega is designed to make highly accurate long-read sequencing accessible to any laboratory MENLO PARK, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), developer…
Program: Oral and Poster Abstracts Type: Oral Session: 655. Multiple Myeloma: Cellular Therapies: Unleashing Cell Therapies Against Myeloma Hematology Disease Topics & Pathways: Research, Clinical…
Program: Oral and Poster Abstracts Type: Oral Session: 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Genomic and Epigenomic Insights into Myeloma Outcomes…
Program: Oral and Poster Abstracts Type: Oral Session: 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Uncovering New Targets and Disease Mechanisms in…
Program: Oral and Poster Abstracts Type: Oral Session: 652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Genes, Cells and Algorithms: Novel…
Program: Oral and Poster Abstracts Type: Oral Session: 654. Multiple Myeloma: Pharmacologic Therapies: Optimizing Therapy in Newly Diagnosed Myeloma and Beyond Hematology Disease Topics &…
Program: Oral and Poster Abstracts Type: Oral Session: 654. Multiple Myeloma: Pharmacologic Therapies: Targeting BCMA Hematology Disease Topics & Pathways: Research, Clinical trials, Antibody Therapy,…
Background: Clonal Hematopoiesis (CH) is a well established confounder in next-generation sequencing (NGS)-based liquid biopsy cancer diagnostics. Misclassification of CH variants as tumor variants can…
Purpose To compare the progression-free survival (PFS) using a treatment regimen selected by molecular profiling (MP) of a patient’s tumor with the PFS for the…
Program: Oral and Poster Abstracts Type: Oral Session: 625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Are We Ready to Move…
Dos 1.000 pacientes de várias idades, submetidos à terapia inovadora, 92% apresentaram melhoras e sem progressão da doença. Eles receberam uma medicação capaz de bloquear…
